Novartis AG (NVS)

NYSE - NYSE Real Time Price. Currency in USD
79.06-0.19 (-0.24%)
As of 2:39 PM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close79.25
Bid79.06 x 300
Ask79.07 x 400
Day's Range78.28 - 79.11
52wk Range69.90 - 95.11
1y Target EstN/A
Market Cap187.61B
P/E Ratio (ttm)28.23
Avg Vol (3m)1,299,531
Dividend & Yield2.72 (3.35%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Prothena Builds On Psoriasis Science For Arthritis Treatment
    Investor's Business Daily21 minutes ago

    Prothena Builds On Psoriasis Science For Arthritis Treatment

    Prothena said late Thursday that it plans to launch phase two testing for a psoriatic arthritis drug.

  • American City Business Journals7 hours ago

    SQZ Biotech nabs $16M funding, hires former Novartis exec

    A startup based at UMass Boston’s Venture Development Center that’s developed a unique way of getting molecules inside living cells has announced a $16 million investment and the hiring of a former Novartis executive as chief business officer. SQZ Biotech, headed by 29-year-old co-founder and CEO Armon Sharei, says the Series B investment was led by two venture firms, NanoDimension and Polaris Partners. Boston-based Polaris was behind a $5 million round the company received in June 2015 , and partner Amy Schulman (also executive chairwoman of SQZ) said that the company has made “remarkable progress” since it was founded in 2013.

  • Investopedia22 hours ago

    Amgen Maintains Migraine Drug Lead (AMGN)

    Amgen leads the migraine drug race by being the first company to publish phase 3 results, but intense competition looms in the future